University of Toledo

Summary

University of Toledo is a medical facility located in Toledo, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. University of Toledo is involved with conducting 207 clinical trials across 353 conditions. There are 8 research doctors associated with this hospital, such as Roland Skeel, MD, Mouhammad Jumaa, MD, Firas G. Petros, and Ahmad Zarzour.

Top PIs

Clinical Trials running at University of Toledo

Bladder Cancer

Lung Cancer

Prostate Cancer

Kidney Cancer

Pancreatic Cancer

Cancer

Non-Small Cell Lung Cancer

Squamous Cell Carcinoma

Renal Cell Carcinoma

Vulval Intraepithelial Neoplasia

EG-70

for Bladder Cancer

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.

Recruiting

1 award

Phase 1 & 2

9 criteria

TARA-002

for Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF. Participants will be enrolled into one of 2 cohorts: Cohort A: * Participants with CIS (± Ta/T1) who are BCG naive, or * Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis Cohort B: * Participants who are BCG unresponsive

Recruiting

1 award

Phase 2

4 criteria

TTX-080 +/− Cetuximab/Pembrolizumab

for Cancer

This trial tests TTX-080, a new drug, alone and with other cancer drugs in patients with hard-to-treat cancers. It works by helping the immune system find and attack cancer cells.

Recruiting

1 award

Phase 1

4 criteria